Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19919515 | 0.77 | TOP2A (0.33) | TOP2ATOP2B | |
| SCHEMBL16852133 | 0.76 | TOP2A (0.30) | TOP2ATOP2B | |
| SCHEMBL13315038 | 0.73 | TOP2A (0.42) | TOP2ATOP2B | |
| SCHEMBL1126303 | 0.72 | TOP2A (0.32) | TOP2ATOP2B | |
| SCHEMBL3548516 | 0.72 | OTUD7B (0.32) | TOP2ATOP2B | |
| SCHEMBL13625472 | 0.69 | TOP2A (0.42) | TOP2ATOP2B | |
| SCHEMBL22679235 | 0.68 | EPHX2 (0.33) | TOP2ATOP2B | |
| SCHEMBL3548520 | 0.68 | TOP2A (0.30) | TOP2ATOP2B | |
| SCHEMBL16750096 | 0.67 | GRIN1 (0.35) | TOP2ATOP2B | |
| SCHEMBL16750095 | 0.67 | GRIN1 (0.33) | TOP2ATOP2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066027-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2024-02-29 | — | — | US | disclosed |
| US-11834447-B2 | Indole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20180134690-A1 | INDAZOLES AND USE THEREOF | PURDUE PHARMA LP (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED | 2018-03-01 | — | — | US | disclosed |
| US-9834543-B2 | Indazoles and use thereof | PURDUE PHARMA L.P. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170283392-A1 | DIBENZAZEPINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2017-10-05 | — | — | US | disclosed |
| US-20170283392-A1 | DIBENZAZEPINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2017-10-05 | — | — | US | disclosed |
| US-9745287-B2 | Pyrimidines and use thereof | PURDUE PHARMA L.P. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745287-B2 | Pyrimidines and use thereof | PURDUE PHARMA L.P. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170001986-A1 | INDAZOLES AND USE THEREOF | PURDUE PHARMA L.P. | 2017-01-05 | — | — | US | disclosed |
| US-20160332992-A1 | PYRIMIDINES AND USE THEREOF | PURDUE PHARMA L.P. | 2016-11-17 | — | — | US | disclosed |
| US-20150284383-A1 | INDOLE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2015-10-08 | — | — | US | disclosed |
| US-7612200-B2 | Inhibitors of protein kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090192307-A1 | INHIBITORS OF PROTEIN KINASES | LOCUS PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20070185098-A1 | Inhibitors of protein kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834447-B2 | Indole derivatives and use thereof | TRPC4, TRPV4, TRPV1 | TOP2A 4632/4885TOP2B 4434/4885 |
| US-20170283392-A1 | DIBENZAZEPINE DERIVATIVES AND USE THEREOF | CACNA1A, CACNA1D, CACNA1S | TOP2A 4308/4885TOP2B 3222/4885 |
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | F2RL1, PARP12, TFPI2 | TOP2A 2113/4885TOP2B 2520/4885 |
| US-20090192307-A1 | INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K1, MAP3K19 | TOP2A 3013/4885TOP2B 3611/4885 |
| US-20170001986-A1 | INDAZOLES AND USE THEREOF | TRPV3, TRPA1, TRPV1 | TOP2A 4448/4885TOP2B 4213/4885 |
| US-20150284383-A1 | INDOLE DERIVATIVES AND USE THEREOF | TRPC4, TRPV4, TRPV1 | TOP2A 4632/4885TOP2B 4434/4885 |
| US-20180134690-A1 | INDAZOLES AND USE THEREOF | TRPV3, TRPA1, TRPV1 | TOP2A 4448/4885TOP2B 4213/4885 |
| US-20240066027-A1 | NOVEL PAR-2 INHIBITORS | F2RL1, F2R, F2RL3 | TOP2A 3785/4885TOP2B 4040/4885 |
| US-20160332992-A1 | PYRIMIDINES AND USE THEREOF | ADORA2B, P2RX2, P2RX3 | TOP2A 2212/4885TOP2B 1626/4885 |
| US-20070185098-A1 | Inhibitors of protein kinases | MAP3K20, MAP3K1, MAP3K19 | TOP2A 3013/4885TOP2B 3611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.